<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Diagnosis and management of adults with chronic kidney disease.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Diagnosis and management of adults with chronic kidney disease. Southfield (MI): Michigan Quality Improvement Consortium; 2013 May. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Diagnosis and management of adults with chronic kidney disease. Southfield (MI): Michigan Quality Improvement Consortium; 2010 Nov. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Cardiovascular disease, unspecified  (429.2); Chronic kidney disease, unspecified  (585.9); Complications affecting other specified body systems, not elsewhere classified, hypertension  (997.91); End stage renal disease  (585.6); Loss of weight  (783.21); Urinary obstruction, unspecified  (599.60)"/><FieldValue Value="MSH: Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Aspirin ; Blood Chemical Analysis ; Blood Pressure Determination ; Blood Urea Nitrogen ; Cardiovascular Diseases ; Chronic Disease ; Clinical Protocols ; Diabetes Mellitus ; Diet, Sodium-Restricted ; Diphtheria-Tetanus-acellular Pertussis Vaccines ; Exercise ; Glomerular Filtration Rate ; Hepatitis B Vaccines ; Hypertension ; Influenza Vaccines ; Kidney Diseases ; Kidney Failure, Chronic ; Kidney Function Tests ; Life Style ; Medication Therapy Management ; Patient Care Planning ; Patient Education as Topic ; Pneumococcal Vaccines ; Referral and Consultation ; Renal Replacement Therapy ; Self Care ; Smoking Cessation ; Urinalysis ; Vaccination ; Weight Loss "/><FieldValue Value="MTH: Albumin To Creatinine Protein Ratio Measurement ; Angiotensin II Type 1 Receptor Blockers ; Angiotensin-Converting Enzyme Inhibitors ; Aspirin ; Blood Chemical Analysis ; Blood electrolyte measurement ; Blood pressure determination ; Blood urea nitrogen measurement ; Body Weight decreased ; Cardiovascular Diseases ; Cessation of smoking ; Chronic disease ; Chronic Kidney Diseases ; Creatinine measurement, serum (procedure) ; Diabetes Mellitus ; Exercise ; Glomerular Filtration Rate ; Hepatitis B Vaccines ; Hypertensive disease ; Influenza virus vaccine ; Kidney Diseases ; Kidney Failure, Chronic ; Kidney Function Tests ; Life Style ; Low sodium diet ; Patient education (procedure) ; Pneumococcal vaccine ; Protein to Creatinine Ratio Measurement ; Self-care interventions ; urinalysis ; Vaccination "/><FieldValue Value="PDQ: acetylsalicyclic acid "/><FieldValue Value="SNOMEDCT_US: Albumin/creatinine ratio measurement  (250745003); Angiotensin-converting enzyme inhibitor agent  (372733002); Angiotensin-converting enzyme inhibitor agent  (41549009); Aspirin  (387458008); Aspirin  (7947003); Blood chemistry  (166312007); Blood electrolyte measurement  (312474003); Blood pressure taking  (46973005); Blood urea nitrogen measurement  (105011006); Blood urea nitrogen measurement  (250623007); Chronic disease  (27624003); Creatinine measurement, serum  (113075003); Diabetes mellitus  (73211009); Diphtheria + tetanus + acellular pertussis vaccine  (429321000124106); Disorder of cardiovascular system  (49601007); Education about alcohol consumption  (281078001); End stage renal disease  (46177005); End stage renal disease  (90688005); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fasting lipid profile  (252150008); Glomerular filtration rate  (80274001); Hypertensive disorder  (38341003); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Kidney disease  (90708001); Life style  (134436002); Life style  (60134006); Low sodium diet  (386619000); Low sodium diet  (437421000124105); Patient education  (311401005); Pneumococcal vaccine  (333598008); Pneumococcal vaccine  (398730001); Protein/creatinine ratio measurement  (250750009); Referral to nephrologist  (306286007); Renal function study  (44277000); Self-care interventions  (384758001); Urinalysis  (167217005); Urinalysis  (27171005); Urinary tract obstruction  (7163005); Weight decreased  (161832001); Weight decreased  (262285001); Weight decreased  (89362005); Weight maintenance regimen management  (410201001)"/><FieldValue Value="UMD: Hemodialysis Units, Renal, Continuous Replacement Therapy  (23-426)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Chronic kidney disease (CKD)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Management" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Nephrology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Health Plans" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To achieve significant, measurable improvements in the diagnosis and management of chronic kidney disease (CKD) through the development and implementation of common evidence-based clinical practice guidelines &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To design concise guidelines that are focused on key management components of CKD to improve outcomes &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Adults at increased risk for chronic kidney disease (CKD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adults with CKD&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Screening/Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Assessment for markers of kidney damage in patients at increased risk for chronic kidney disease (CKD) (e.g., diabetes mellitus, hypertension, family history of kidney disease, etc.):&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Measure blood pressure (BP) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obtain serum creatinine and estimated glomerular filtration rate (GFR) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Protein-to-creatinine ratio or albumin-to-creatinine ratio specimen &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Urinalysis, fasting lipid profile, electrolytes, blood urea nitrogen (BUN) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Evaluation and management of comorbid conditions such as diabetes, hypertension, urinary tract obstruction, cardiovascular disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient education on lifestyle changes such as dietary sodium intake, weight maintenance, weight loss, exercise, alcohol intake, smoking cessation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Review of medications for dose adjustment, drug interactions, adverse effects, and therapeutic levels &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Vaccine update &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Development of clinical action plan for each patient based on CKD stage &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incorporation of self-management behaviors into treatment plan at all stages &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Management according to kidney disease stage&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Monitoring GFR &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Smoking cessation and maintenance of BP and lipid goals &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Avoiding non-steroidal anti-inflammatory drugs (NSAIDs) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Nephrology referral or consult if abnormalities of anemia, parathyroid hormone (PTH), vitamin D, calcium, and phosphorus, or GFR &amp;lt;45 mL/min &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Angiotensin-converting enzyme (ACE) inhibitor/angiotensin receptor blocker (ARB) therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;CKD education class &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Renal replacement therapy &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Michigan Quality Improvement Consortium (MQIC) health care analyst conducts a search of current literature in support of the guideline topic. Computer database searches are used to identify published studies, existing protocols and/or national guidelines on the selected topic developed by organizations such as the American Diabetes Association, American Heart Association, American Academy of Pediatrics, etc. If available, clinical practice guidelines from participating MQIC health plans and Michigan health systems are also used to develop a framework for the new guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For the current update of the guideline the following databases were searched from 2009 to 2013: United States Preventive Services Task Force (USPSTF), American College of Physicians, National Kidney Foundation, Google, PubMed, Annals of Internal Medicine. No inclusion or exclusion criteria were applied. Specific search terms used were chronic kidney disease (CKD), CKD screening, CKD stages.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&#xD;&#xA;&lt;ol start=&quot;1&quot; type=&quot;A&quot;&gt;&#xD;&#xA;&lt;li&gt;Randomized controlled trials&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Controlled trials, no randomization&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Observational studies&lt;/li&gt;&#xD;&#xA;&lt;li&gt;Opinion of expert panel&lt;/li&gt;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Using information obtained from literature searches and available health plan guidelines on the designated topic, the Michigan Quality Improvement Consortium (MQIC) health care analyst prepares a draft guideline to be reviewed by the medical directors' committee at one of their scheduled meetings. Priority is given to recommendations with [A] and [B] levels of evidence (see the &quot;Rating Scheme for the Strength of the Evidence&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The initial draft guideline is reviewed, evaluated, and revised by the committee resulting in draft two of the guideline. Additionally, the Michigan Academy of Family Physicians participates in guideline development at the onset of the process and throughout the guideline development procedure. The MQIC guideline feedback form and draft two of the guideline are distributed to the medical directors, as well as the MQIC measurement and implementation group members, for review and comments. Feedback from members is collected by the MQIC health care analyst and prepared for review by the medical directors' committee at their next scheduled meeting. The review, evaluation, and revision process with several iterations of the guideline may be repeated over several meetings before consensus is reached on a final draft guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="External Peer Review" /><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;When consensus is reached on the final draft guideline, the medical directors approve the guideline for external distribution to practitioners with review and comments requested via the Michigan Quality Improvement Consortium (MQIC) health plans (health care analyst distributes final draft to medical directors' committee, measurement and implementation groups to solicit feedback).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst also forwards the approved guideline draft to appropriate state medical specialty societies and physicians with expertise in the related field for their input. After all feedback is received from external reviews, it is presented for discussion at the next scheduled committee meeting. Based on feedback, subsequent guideline review, evaluation, and revision may be required prior to final guideline approval.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC Medical Directors approved this updated guideline in May 2013.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The level of evidence grades (&lt;strong&gt;A-D&lt;/strong&gt;) are provided for the most significant recommendations and are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Screening and Diagnosis&lt;/span&gt; [D]&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;All Adults at Increased Risk for Chronic Kidney Disease (CKD)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;For patients at increased risk for CKD (e.g., diabetes mellitus, hypertension, family history of kidney disease, etc.) assess for markers of kidney damage:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Measure blood pressure (BP) &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obtain serum creatinine and estimated glomerular filtration rate (GFR).&lt;sup&gt;1&lt;/sup&gt; If &amp;lt;60 mL/min, repeat within 90 days. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Protein-to-creatinine ratio or albumin-to-creatinine ratio (first morning or random spot urine specimen) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Urinalysis, fasting lipid profile, electrolytes, blood urea nitrogen (BUN) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Frequency&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Semi-annual BP monitoring; more frequent monitoring if indicated &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitor GFR every 1&amp;ndash;2 years &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;1&lt;/sup&gt; If not calculated by lab, refer to the &lt;a href=&quot;http://www.kidney.org/professionals/tools/&quot; title=&quot;National Kidney Foundation Web site&quot;&gt;National Kidney Foundation Web site&lt;/a&gt; for GFR calculator.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Risk Factor Management and Patient Education&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;All Adults at Increased Risk for CKD&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Evaluation and management of comorbid conditions (e.g., diabetes mellitus, hypertension, urinary tract obstruction, cardiovascular disease)&lt;sup&gt;2&lt;/sup&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Educate on therapeutic lifestyle changes based on GFR: weight maintenance if body mass index (BMI) &amp;lt;25, weight loss if BMI &amp;ge;25, exercise and physical activity, dietary counseling, moderation of alcohol intake, smoking cessation &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Frequency&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At each routine health exam&lt;/p&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;sup&gt;2&lt;/sup&gt;See the National Guideline Clearinghouse (NGC) summaries of the Michigan Quality Improvement Consortium (MQIC) guidelines: &lt;a href=&quot;/content.aspx?id=46655&quot; title=&quot;Guideline #9934&quot;&gt;Management of diabetes mellitus&lt;/a&gt;, &lt;a href=&quot;/content.aspx?id=47288&quot; title=&quot;Guideline #10039&quot;&gt;Medical management of adults with hypertension&lt;/a&gt;, &lt;a href=&quot;/content.aspx?id=47289&quot; title=&quot;Guideline #10040&quot;&gt;Screening and management of hypercholesterolemia&lt;/a&gt;, and &lt;a href=&quot;/content.aspx?id=46654&quot; title=&quot;Guideline #9933&quot;&gt;Management of overweight and obesity in the adult&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Core Principles of Treatment&lt;/span&gt; [D]&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Adults with CKD&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Review medications for dose adjustment, drug interactions, adverse effects, therapeutic levels &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Update vaccines: hepatitis B virus (HBV); influenza; tetanus/diphtheria acellular pertussis (Tdap); and Pneumovax &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dietary sodium intake &amp;lt;2.4 g/d recommended for patients with CKD and hypertension &lt;strong&gt;[A]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incorporate self-management behaviors into treatment plan at all stages of CKD &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Develop clinical action plan for each patient, based on disease stage as defined by the National Kidney Foundation, &lt;a href=&quot;http://www.kidney.org/professionals/kdoqi/&quot; title=&quot;K/DOQI Web site&quot;&gt;Kidney Disease Outcomes Quality Initiative (K/DOQI)&lt;/a&gt; &lt;strong&gt;[B]&lt;/strong&gt; &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Frequency&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;At each routine health exam&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Adults with CKD&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Stage 1 (GFR &amp;ge;90 mL/min)&lt;/strong&gt;: Monitor GFR annually, smoking cessation, consider angiotensin-converting enzyme (ACE) inhibitor and/or angiotensin receptor blocker (ARB) therapy, BP goal &amp;lt;130/80, low density lipoprotein-cholesterol (LDL-C) goal &amp;lt;100. Avoid non-steroidal anti-inflammatory drugs (NSAIDs). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Stage 2 (GFR 60&amp;ndash;89 mL/min)&lt;/strong&gt;: Nephrology referral if GFR decline &amp;gt;4mL/min/yr, maintain BP and lipid goals as above &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Stage 3 (GFR 30&amp;ndash;59 mL/min)&lt;/strong&gt;: Nephrology consult if abnormalities of anemia, parathyroid hormone (PTH), vitamin D (VitD), calcium, and phosphorus, or GFR &amp;lt;45 mL/min. Avoid contrast, if possible. Low-dose aspirin (ASA) allowed. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Stage 4 (GFR 15&amp;ndash;29 mL/min)&lt;/strong&gt;: Nephrology referral. CKD education classes. Avoid ASA. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Stage 5 (GFR &amp;lt;15 mL/min)&lt;/strong&gt;: Renal replacement therapy &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Frequency&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;As indicated&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Levels of Evidence for the Most Significant Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: upper-alpha;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Randomized controlled trials &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Controlled trials, no randomization &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Observational studies &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Opinion of expert panel &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of evidence is provided for the most significant recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline is based on Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. &lt;em&gt;Ann Intern Med&lt;/em&gt;. 2012;156:570-581.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Through a collaborative approach to developing and implementing common clinical practice guidelines and performance measures for the diagnosis and management of adults with chronic kidney disease (CKD), Michigan health plans will achieve consistent delivery of evidence-based services and better health outcomes. This approach also will augment the practice environment for physicians by reducing the administrative burdens imposed by compliance with diverse health plan guidelines and associated requirements.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline lists core management steps. Individual patient considerations and advances in medical science may supersede or modify these recommendations.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Approved Michigan Quality Improvement Consortium (MQIC) guidelines are disseminated through email, U.S. mail, and websites.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst prepares approved guidelines for distribution. Portable Document Format (PDF) versions of the guidelines are used for distribution.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst distributes approved guidelines to MQIC membership via email.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to Web site vendor to post approved guidelines to the &lt;a href=&quot;http://www.mqic.org/&quot; title=&quot;MQIC Web site&quot;&gt;MQIC Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst completes an annual statewide postcard mailing to physicians in all areas of medicine including primary care and specialties. The postcard provides the complete list of MQIC guidelines and includes which guidelines have been recently revised, which are coming up for revision, and any new published guidelines.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The statewide mailing list is derived from the Blue Cross Blue Shield of Michigan (BCBSM) provider database. Approximately 95% of the state's M.D.'s and 96% of the state's D.O.'s are included in the database.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The MQIC health care analyst submits request to the National Guideline Clearinghouse (NGC) to post approved guidelines to the &lt;a href=&quot;http://www.guideline.gov&quot; title=&quot;NGC Web site&quot; target=&quot;_blank&quot;&gt;NGC Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Michigan Quality Improvement Consortium. Diagnosis and management of adults with chronic kidney disease. Southfield (MI): Michigan Quality Improvement Consortium; 2013 May. 1 p. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This guideline is based on Screening for, Monitoring, and Treatment of Chronic Kidney Disease Stages 1 to 3: A Systematic Review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. &lt;em&gt;Ann Intern Med&lt;/em&gt;. 2012;156:570-581.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2006 Nov (revised 2013 May)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Michigan Quality Improvement Consortium - Professional Association" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Michigan Quality Improvement Consortium Medical Directors' Committee&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Physician representatives from the 13 participating Michigan Quality Improvement Consortium health plans, Michigan State Medical Society, Michigan Osteopathic Association, Michigan Association of Health Plans, Michigan Department of Community Health, Michigan Peer Review Organization, and the University of Michigan Health System&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Standard disclosure is requested from all individuals participating in the Michigan Quality Improvement Consortium (MQIC) guideline development process, including those parties who are solicited for guideline feedback (e.g., health plans, medical specialty societies). Additionally, members of the MQIC Medical Directors' Committee are asked to disclose all commercial relationships as well.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Michigan Quality Improvement Consortium. Diagnosis and management of adults with chronic kidney disease. Southfield (MI): Michigan Quality Improvement Consortium; 2010 Nov. 1 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.mqic.org/pdf/mqic_diagnosis_and_management_of_adults_with_chronic_kidney_disease_cpg.pdf&quot; title=&quot;Michigan Quality Improvement Consortium Web site&quot;&gt;Michigan Quality Improvement Consortium Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on July 13, 2007. The information was verified by the guideline developer on July 16, 2007. This summary was updated by ECRI Institute on March 21, 2008 following the FDA advisory on Erythropoiesis Stimulating Agents. This summary was updated by ECRI Institute on August 15, 2008 following the U.S. Food and Drug Administration advisory on Erythropoiesis Stimulating Agents (ESAs). This summary was updated by ECRI Institute on June 8, 2009. The updated information was verified by the guideline developer on June 30, 2009. This summary was updated by ECRI Institute on April 1, 2010 following the U.S. Food and Drug Administration advisory on Erythropoiesis-Stimulating Agents (ESAs). This NGC summary was updated by ECRI Institute on February 23, 2011. The updated information was verified by the guideline developer on February 28, 2011. This summary was updated by ECRI Institute on August 22, 2013. The updated information was verified by the guideline developer on October 2, 2013.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary is based on the original guideline, which may be reproduced with the citation developed by the Michigan Quality Improvement Consortium.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
